$RGNX News

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23

Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

REGENXBIO (NASDAQ:RGNX) Beats Q2 EPS but Misses Revenue; Duchenne Gene Therapy Timeline Reaffirmed

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Prices Offering Of 10,003,889 Shares At $9.00 Per Share And 1,111,111 Pre-Funded Warrants At $8.9999 Per Warrant

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO Plans To Commence $100M Common Stock Offering

REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone

HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $26 Price Target

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy

FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy

Baird Maintains Outperform on Regenxbio, Raises Price Target to $32

Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $18